Precision BioSciences Inc (FRA:PBS0)
€ 9.85 -0.1 (-0.98%) Market Cap: 65.13 Mil Enterprise Value: -34.23 Mil PE Ratio: 0 PB Ratio: 2.02 GF Score: 56/100

Precision BioSciences Inc at H C Wainwright Global Investment Conference (Virtual) Transcript

Sep 13, 2022 / 08:30PM GMT
Release Date Price: €48.27
Patrick Trucchio
H.C. Wainwright & Co., LLC - Analyst

Hello, everyone, and good afternoon, and welcome back to H.C. Wainwright's 24th Annual Global Investment Hybrid Conference. My name is Patrick Trucchio. I'm a senior healthcare analyst at H.C. Wainwright.

It's my pleasure to introduce our next presenter. I'd like to welcome Michael Amoroso, CEO; Derek Jantz, CSO; and Alan List, CMO of Precision BioSciences, a clinical-stage gene-editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies.

So maybe if we could just begin with an overview of Precision's ARCUS platform, how it's differentiated versus other approaches in the field such as CRISPR.

Michael Amoroso;Derek Jantz
Precision BioSciences, Inc. - President & CEO;Precision BioSciences, Inc. - Chief

Yes, just a quick one, Patrick. And Wainwright, thanks for having us. We're excited to be with you. And I'm going to turn it over to our CSO and Co-Founder, Derek Jantz, for an overview on the organization.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot